Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

Research output: Contribution to journalArticle

Details

Authors
  • S. Rule
  • W. Jurczak
  • M. Jerkeman
  • C. Rusconi
  • M. Trneny
  • F. Offner
  • D. Caballero
  • C. Joao
  • M. Witzens-Harig
  • G. Hess
  • I. Bence-Bruckler
  • S. G. Cho
  • C. Thieblemont
  • W. Zhou
  • T. Henninger
  • J. Goldberg
  • J. Vermeulen
  • M. Dreyling
Organisations
External organisations
  • Plymouth University
  • Jagellonian University
  • Skåne University Hospital
  • Niguarda Hospital
  • Ghent University Hospital
  • University Hospital of Salamanca
  • Champalimaud Foundation
  • University Hospital Heidelberg
  • University of Mainz
  • The Ottawa Hospital
  • Saint-Louis Hospital, Paris
  • Janssen Research & Development LLC
  • General University Hospital in Prague
  • Instituto Português de Oncologia do Porto Francisco Gentil (IPO)
  • Seoul St. Mary's Hospital
  • Paris Diderot University
  • University Hospital Munich
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)1799-1803
JournalLeukemia
Volume32
Issue number8
Early online date2018 Feb 2
Publication statusPublished - 2018 Aug
Publication categoryResearch
Peer-reviewedYes